相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial
Sherene Loi et al.
LANCET ONCOLOGY (2019)
Genomic correlates of response to immune checkpoint blockade
Tanya E. Keenan et al.
NATURE MEDICINE (2019)
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors
K. M. Heinhuis et al.
ANNALS OF ONCOLOGY (2019)
Molecular and Genomic Determinants of Response to Immune Checkpoint Inhibition in Cancer
Russell W. Jenkins et al.
ANNUAL REVIEW OF MEDICINE, VOL 69 (2018)
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Bertrand Routy et al.
SCIENCE (2018)
Rationale and Emerging Strategies for Immune Checkpoint Blockade in Soft Tissue Sarcoma
Amy J. Wisdom et al.
CANCER (2018)
Selective FcγR Co-engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens
Jeremy D. Waight et al.
CANCER CELL (2018)
Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy
Yinghao Zhao et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2018)
Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome
Marie-Andree Forget et al.
CLINICAL CANCER RESEARCH (2018)
Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors
Julius Strauss et al.
CLINICAL CANCER RESEARCH (2018)
Armed oncolytic viruses: A kick-start for anti-tumor immunity
J. F. de Graaf et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2018)
Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T
Dok Hyun Yoon et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Cancer immunotherapy using trabectedin and nivolumab in advanced soft tissue sarcoma: A retrospective analysis.
Erlinda Maria Gordon et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study
Franck Pages et al.
LANCET (2018)
Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials
Sandra P. D'Angelo et al.
LANCET ONCOLOGY (2018)
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Dal Fukurnura et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Oncogenic pathways that affect antitumor immune response and immune checkpoint blockade therapy
Xianda Zhao et al.
PHARMACOLOGY & THERAPEUTICS (2018)
Personalized vaccines for cancer immunotherapy
Ugur Sahin et al.
SCIENCE (2018)
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Vyara Matson et al.
SCIENCE (2018)
The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies
Laurence Zitvogel et al.
SCIENCE (2018)
Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis
Danielle Benedict Sacdalan et al.
ONCOTARGETS AND THERAPY (2018)
Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGF beta enhance the efficacy of cancer immunotherapy
Rajani Ravi et al.
NATURE COMMUNICATIONS (2018)
Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1c259 T Cells in Synovial Sarcoma
Sandra P. D'Angelo et al.
CANCER DISCOVERY (2018)
Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas A Phase 2 Clinical Trial
Maud Toulmonde et al.
JAMA ONCOLOGY (2018)
Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
Priyanka B. Subrahmanyam et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Targeting adenosine for cancer immunotherapy
Robert D. Leone et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA)
Patrick Danaher et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Impact of L-Arginine Metabolism on Immune Response and Anticancer Immunotherapy
Sun-Hee Kim et al.
FRONTIERS IN ONCOLOGY (2018)
Transforming Growth Factor-β Signaling Plays a Pivotal Role in the Interplay Between Osteosarcoma Cells and Their Microenvironment
Franck Verrecchia et al.
FRONTIERS IN ONCOLOGY (2018)
Pilot study of NY-ESO-1c259 T cells in advanced myxoid/round cell liposarcoma.
Sandra P. D'Angelo et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Phase I open-label, ascending dose trial of AGEN1884, an anti-CTLA-4 monoclonal antibody, in advanced solid malignancies: Dose selection for combination with PD-1 blockade.
Breelyn A. Wilky et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A phase II study of talimogene laherparepvec (T-VEC) and pembrolizumab in patients with metastatic sarcoma.
Ciara Marie Kelly et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
IMMUNOSARC: A collaborative Spanish (GEIS) and Italian (ISG) Sarcoma Groups phase I/II trial of sunitinib plus nivolumab in selected bone and soft tissue sarcoma subtypes—Results of the phase I part.
Javier Martin Broto et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan et al.
NATURE (2018)
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
Peng Jiang et al.
NATURE MEDICINE (2018)
Biological significance and prognostic relevance of peripheral blood neutrophil-to-lymphocyte ratio in soft tissue sarcoma
Jason Yongsheng Chan et al.
SCIENTIFIC REPORTS (2018)
A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti-PD-(L)1 and Anti-CTLA-4 in Preclinical Models
Stephen B. Willingham et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Targeting T Cell Metabolism for Improvement of Cancer Immunotherapy
Thibault Le Bourgeois et al.
FRONTIERS IN ONCOLOGY (2018)
Non-invasive biomarkers derived from the extracellular matrix associate with response to immune checkpoint blockade (anti-CTLA-4) in metastatic melanoma patients
Christina Jensen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Transforming of the Tumor Microenvironment: Implications for TGF- Inhibition in the Context of Immune-Checkpoint Therapy
Stefanie Loeffek
JOURNAL OF ONCOLOGY (2018)
Carbohydrate Targets for CAR T Cells in Solid Childhood Cancers
Claudia Rossig et al.
FRONTIERS IN ONCOLOGY (2018)
Oncolytic viruses and checkpoint inhibitors: combination therapy in clinical trials
Christopher J. LaRocca et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2018)
CTLA4 methylation predicts response to anti-PD-1 and anti-CTLA-4 immunotherapy in melanoma patients
Diane Goltz et al.
JCI INSIGHT (2018)
Comprehensive analysis of the clinical immuno-oncology landscape
J. Tang et al.
ANNALS OF ONCOLOGY (2018)
Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance
Young-Jun Park et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2018)
Radiotherapy and checkpoint inhibitors: a winning new combination?
Eric C. Ko et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2018)
Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab
Sandra P. D'Angelo et al.
CLINICAL CANCER RESEARCH (2017)
PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors
Adrian M. Seifert et al.
CLINICAL CANCER RESEARCH (2017)
The concept of immune surveillance against tumors. The first theories
Domenico Ribatti
ONCOTARGET (2017)
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
Hussein A. Tawbi et al.
LANCET ONCOLOGY (2017)
Arginine Deprivation Inhibits the Warburg Effect and Upregulates Glutamine Anaplerosis and Serine Biosynthesis in ASS1-Deficient Cancers
Jeff Charles Kremer et al.
CELL REPORTS (2017)
A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice
Jeremy B. Foote et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Cancer immunotherapy: Historical Perspective of a Clinical Revolution and emerging Preclinical Animal Models
William K. Decker et al.
FRONTIERS IN IMMUNOLOGY (2017)
A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells
Justin M. David et al.
ONCOIMMUNOLOGY (2017)
Transforming growth factor-β1 signaling promotes epithelial-mesenchymal transition-like phenomena, cell motility, and cell invasion in synovial sarcoma cells
Yan Qi et al.
PLOS ONE (2017)
Safety and clinical activity of adenosine A2a receptor (A2aR) antagonist, CPI-444, in anti-PD1/PDL1 treatment-refractory renal cell (RCC) and non-small cell lung cancer (NSCLC) patients.
Lawrence Fong et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas
Alexander J. Lazar et al.
CELL (2017)
Migrating into the Tumor: a Roadmap for T Cells
Lieke L. van der Woude et al.
TRENDS IN CANCER (2017)
Roles for Innate Immunity in Combination Immunotherapies
Kelly D. Moynihan et al.
CANCER RESEARCH (2017)
T-Cell Infiltration and Clonality Correlate With Programmed Cell Death Protein 1 and Programmed Death-Ligand 1 Expression in Patients With Soft Tissue Sarcomas
Seth M. Pollack et al.
CANCER (2017)
Characterization of anti-CD19 chimeric antigen receptor (CAR) T cell-mediated tumor microenvironment immune gene profile in a multicenter trial (ZUMA-1) with axicabtagene ciloleucel (axi-cel, KTE-C19).
Jerome Galon et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Current status of immunotherapy for gastrointestinal stromal tumor
Y. Tan et al.
CANCER GENE THERAPY (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
Glutaminase inhibition with CB-839 enhances anti-tumor activity of PD-1 and PD-L1 antibodies by overcoming a metabolic checkpoint blocking T cell activation
Matt Gross et al.
CANCER RESEARCH (2016)
The Basis of Oncoimmunology
A. Karolina Palucka et al.
CELL (2016)
Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015
J. Galon et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The cancer immunogram
Christian U. Blank et al.
SCIENCE (2016)
A metabolic synthetic lethal strategy with arginine deprivation and chloroquine leads to cell death in ASS1-deficient sarcomas
Gregory R. Bean et al.
CELL DEATH & DISEASE (2016)
Tumor CTLA-4 overexpression predicts poor survival in patients with nasopharyngeal carcinoma
Pei-Yu Huang et al.
ONCOTARGET (2016)
Current clinical trials testing the combination of immunotherapy with radiotherapy
Josephine Kang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies
Matthew Reilley et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Phase 2 study of nivolumab in metastatic Ieiomyosarcoma of the uterus.
Suzanne George et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Abscopal effects of radiation therapy: A clinical review for the radiobiologist
Shankar Siva et al.
CANCER LETTERS (2015)
Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
Amita Patnaik et al.
CLINICAL CANCER RESEARCH (2015)
Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment
Sandra P. D'Angelo et al.
HUMAN PATHOLOGY (2015)
Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma
Nabil Ahmed et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
James N. Kochenderfer et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
Dirk Schadendorf et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment
Vinit Kumar et al.
IMMUNOLOGY (2014)
Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Going viral with cancer immunotherapy
Brian D. Lichty et al.
NATURE REVIEWS CANCER (2014)
Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
Caroline J. Breitbach et al.
CANCER RESEARCH (2013)
Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance
Laurence Zitvogel et al.
IMMUNITY (2013)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells
Mark J. Selby et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Clinical implication of pretreatment neutrophil to lymphocyte ratio in soft tissue sarcoma
O. K. Idowu et al.
BIOMARKERS (2012)
Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer
Sandra Salvi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4
J. D. Dias et al.
GENE THERAPY (2012)
Deletion of TGF-β signaling in myeloid cells enhances their anti-tumorigenic properties
Sergey V. Novitskiy et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2012)
Oncolytic virotherapy
Stephen J. Russell et al.
NATURE BIOTECHNOLOGY (2012)
TGF-β is responsible for NK cell immaturity during ontogeny and increased susceptibility to infection during mouse infancy
Jeffrey P. Marcoe et al.
NATURE IMMUNOLOGY (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
Vinod P. Balachandran et al.
NATURE MEDICINE (2011)
Sunitinib Inhibition of Stat3 Induces Renal Cell Carcinoma Tumor Cell Apoptosis and Reduces Immunosuppressive Cells
Hong Xin et al.
CANCER RESEARCH (2009)
Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients
James H. Finke et al.
CLINICAL CANCER RESEARCH (2008)
CTLA-4 disrupts ZAP70 microcluster formation with reduced T cell/APC dwell times and calcium mobilization
Helga Schneider et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2008)
Angiogenesis-promoting gene patterns in alveolar soft part sarcoma
Alexander J. F. Lazar et al.
CLINICAL CANCER RESEARCH (2007)
PD-1 and PD-1 ligands: from discovery to clinical application
Taku Okazaki et al.
INTERNATIONAL IMMUNOLOGY (2007)
TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance
DA Thomas et al.
CANCER CELL (2005)
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms
RV Parry et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Regulation of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA-synthetase by CTLA-4-Fc in human CD4+ T cells
A Boasso et al.
BLOOD (2005)
Suppressor activity of anergic T cells induced by IL-10-treated human dendritic cells:: association with IL-2- and CTLA-4-dependent G1 arrest of the cell cycle regulated by p27Kip1
S Kubsch et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2003)
分享论文
